A Single Centre Experience with Phenotype Dependent Perioperative Chemotherapy for Primary Breast Cancer

• 作者: Adél Ambrus Balázs Hillier Gabriella Herodek Ilona Laszip István Sip?cz Károly Kocsis Kofi Agyemang-Prempeh Mária Mák Tamás Kullmann Tamás Pintér
• 来源期刊: 癌症治疗(英文)
• 学科: 医学
• 关键词: Breast Cancer CARBOPLATIN TRASTUZUMAB ADJUVANT NEOADJUVANT
• 年，卷（期）: 2019,（1）
• 页码范围: 21-27
• 页数: 7页
• 分类号: R73

摘要

Background: Standard adjuvant or neo-adjuvant chemotherapy of primary breast cancers consists of docetaxel and the combination of anthracyclin-cyclophosphamide in two steps. According to international literature, the neo-adjuvant treatment of triple negative tumours by the combination of docetaxel-carboplatin allows a high rate of pathological complete remission and the adjuvant treatment of small, node negative HER2+ tumours by the combination of paclitaxel-trastuzumab allows a negligible recurrence rate together with a very good tolerance. Methods: Our aim was the retrospective analysis of the alternative chemotherapy regimens in our patient population. Results: The neo-adjuvant docetaxel-carboplatin allowed a 55% pathological complete remission rate among 20 patients. With the adjuvant paclitaxel-trastuzumab, we did not notice any recurrence among 5 patients at a median follow-up of 18 months. Conclusion: Our results correspond to the literature data. The spread of the protocols in the clinical practice is proposed.